CN117255802A - 抗cd30l抗体和其用途 - Google Patents

抗cd30l抗体和其用途 Download PDF

Info

Publication number
CN117255802A
CN117255802A CN202280028982.8A CN202280028982A CN117255802A CN 117255802 A CN117255802 A CN 117255802A CN 202280028982 A CN202280028982 A CN 202280028982A CN 117255802 A CN117255802 A CN 117255802A
Authority
CN
China
Prior art keywords
cdr
amino acid
acid sequence
seq
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280028982.8A
Other languages
English (en)
Chinese (zh)
Inventor
杰西-法拉·菲克特奥
马克·伦萧
乔汉·法兰森
奥立维尔·劳伦特
伯顿·巴奈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometheus Biosciences Inc
Original Assignee
Dr Falk Pharma GmbH
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma GmbH, Prometheus Biosciences Inc filed Critical Dr Falk Pharma GmbH
Priority to CN202410189800.6A priority Critical patent/CN118047872A/zh
Publication of CN117255802A publication Critical patent/CN117255802A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202280028982.8A 2021-02-17 2022-02-16 抗cd30l抗体和其用途 Pending CN117255802A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410189800.6A CN118047872A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17
US63/150,373 2021-02-17
PCT/US2022/016565 WO2022177963A1 (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410189800.6A Division CN118047872A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Publications (1)

Publication Number Publication Date
CN117255802A true CN117255802A (zh) 2023-12-19

Family

ID=82931610

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280028982.8A Pending CN117255802A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途
CN202410189800.6A Pending CN118047872A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410189800.6A Pending CN118047872A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Country Status (20)

Country Link
US (4) US20240254246A1 (enExample)
EP (1) EP4294840A4 (enExample)
JP (2) JP7559257B2 (enExample)
KR (1) KR20230157356A (enExample)
CN (2) CN117255802A (enExample)
AR (1) AR124895A1 (enExample)
AU (1) AU2022224561A1 (enExample)
BR (1) BR112023016445A2 (enExample)
CA (1) CA3208060A1 (enExample)
CL (2) CL2023002393A1 (enExample)
CO (1) CO2023011962A2 (enExample)
CR (1) CR20230445A (enExample)
EC (1) ECSP23070234A (enExample)
GE (4) GEAP202616911A (enExample)
IL (1) IL305146A (enExample)
JO (1) JOP20230186A1 (enExample)
MX (1) MX2023009621A (enExample)
PE (1) PE20231680A1 (enExample)
TW (1) TW202302637A (enExample)
WO (1) WO2022177963A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND USES THEREOF
PE20231680A1 (es) * 2021-02-17 2023-10-19 Dr Falk Pharma Gmbh Anticuerpos anti-cd30l y usos de estos
EP4359425B1 (en) 2021-06-21 2026-08-05 Juvena Therapeutics, Inc. Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury
AU2023315888A1 (en) * 2022-07-25 2025-02-06 Prometheus Biosciences, Inc. Anti-cd30l antibodies, formulations therefor, and uses thereof
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
KR20260074680A (ko) * 2023-09-12 2026-05-26 암젠 인크 항-cd30l 항체 및 이의 용도
CN122055382A (zh) * 2023-10-03 2026-05-15 国立大学法人京都大学 靶向人cd153的抗体和嵌合抗原受体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE311895T1 (de) * 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1667730T3 (da) 2003-08-20 2013-09-23 Univ Miami Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
WO2013059732A1 (en) * 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
CN104507968B (zh) * 2012-04-27 2019-02-05 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
EP2945865B1 (en) 2013-01-18 2019-01-09 LORD Corporation Active vibration control devices, systems, and methods
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
WO2017127537A1 (en) 2016-01-19 2017-07-27 Thomas Blumenthal Down syndrome biomarkers and uses thereof
PT3774897T (pt) * 2018-04-30 2023-11-10 Cedars Sinai Medical Center Métodos e sistemas para seleção e tratamento de pacientes com doenças inflamatórias
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
PE20231680A1 (es) * 2021-02-17 2023-10-19 Dr Falk Pharma Gmbh Anticuerpos anti-cd30l y usos de estos

Also Published As

Publication number Publication date
PE20231680A1 (es) 2023-10-19
CL2023002393A1 (es) 2024-03-22
CA3208060A1 (en) 2022-08-25
JOP20230186A1 (ar) 2023-08-09
ECSP23070234A (es) 2023-10-31
GEAP202616911A (en) 2026-04-27
JP2024509746A (ja) 2024-03-05
CN118047872A (zh) 2024-05-17
EP4294840A4 (en) 2025-06-11
EP4294840A1 (en) 2023-12-27
BR112023016445A2 (pt) 2023-12-12
US20230060624A1 (en) 2023-03-02
US12516126B2 (en) 2026-01-06
CR20230445A (es) 2023-11-14
GEP20257791B (en) 2025-09-10
GEAP202516710A (en) 2025-05-13
KR20230157356A (ko) 2023-11-16
WO2022177963A1 (en) 2022-08-25
IL305146A (en) 2023-10-01
MX2023009621A (es) 2023-10-31
CO2023011962A2 (es) 2023-09-29
US11866505B2 (en) 2024-01-09
TW202302637A (zh) 2023-01-16
US20260209372A1 (en) 2026-07-23
JP7559257B2 (ja) 2024-10-01
JP2025004013A (ja) 2025-01-14
US20240254246A1 (en) 2024-08-01
AU2022224561A9 (en) 2023-10-05
US20240092923A1 (en) 2024-03-21
AU2022224561A1 (en) 2023-09-28
GEAP202416351A (en) 2024-02-12
CL2026000881A1 (es) 2026-06-12
AR124895A1 (es) 2023-05-17

Similar Documents

Publication Publication Date Title
JP7559257B2 (ja) 抗ｃｄ３０ｌ抗体およびその使用
CN108752476B (zh) 一种pdl-1抗体、其药物组合物及其用途
TW202128753A (zh) 抗tslp抗體及其用途
WO2019149269A1 (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
JP7858665B2 (ja) Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
KR20180002782A (ko) 전립선 특이적 막 항원(psma) 이중특이성 결합제 및 그의 용도
JP7419238B2 (ja) Ｐｄ１結合剤
AU2018348430B2 (en) Antibodies targeting PDL1 and methods of use thereof
JP2022540620A (ja) 胸腺間質性リンパ球新生因子（ｔｓｌｐ）受容体シグナル伝達に干渉する薬剤
CN115461366A (zh) 抗ox40抗体及其用途
KR20260039798A (ko) ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법
US20250340660A1 (en) Anti-cd30l antibodies, formulations therefor, and uses thereof
JP2025020172A (ja) Ｃｄ１３７を標的とする抗体およびその使用方法
TW202513584A (zh) Ｅｎｐｐ３及ｃｄ３結合劑及其使用方法
EP4554976A1 (en) Ang-2/vegf antibodies and uses thereof
CN117295762A (zh) 抗cd122抗体及其用途
RU2834227C1 (ru) Анти-tslp антитело и его применение
CN116284406A (zh) 一种pd-1结合蛋白及其应用
WO2026002175A1 (zh) 靶向ilt7和cd89的髓细胞衔接子抗体及其用途
HK40125826A (en) Anti-l1cam antibodies and uses thereof
JP2024544924A (ja) トランスサイレチン（ｔｔｒ）単量体結合抗体
JP2023523760A (ja) 免疫グロブリン変異体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20260520

Address after: California, USA

Applicant after: Prometheus Biosciences

Country or region after: U.S.A.

Address before: California, USA

Applicant before: Prometheus Biosciences

Country or region before: U.S.A.

Applicant before: DR. FALK PHARMA GmbH

Country or region before: Germany